Ausgewählte Publikationen

1. Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events.

Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ. Clin Cancer Res. 2011 Apr 19.

2. Harman A.N.; Kraus M.; Bye Ch.R.; Byth K.; Turville S.G.; Tang O.; Mercier S.K.; Stern J.L.; Driessen C., Slobedman B, Cunningham A.L., HIV-1 Infected Dendritic Cells Show Two Phases of Gene Expression Changes With Lysosomal Enzyme Activity Decreased During the Second Phase. Blood 2009, 114(1):85-94

3. Hillaert U, Verdoes M, Florea BI, Saragliadis A, Habets KL, Kuiper J, Van Calenbergh S, Ossendorp F, van der Marel GA, Driessen C, Overkleeft HS. Receptor-mediated targeting of cathepsins in professional antigen presenting cells. Angew Chem Int Ed Engl. 2009;48(9):1629-32

4. Clerc J, Florea BI, Kraus M, Groll M, Huber R, Bachmann AS, Dudler R, Driessen C, Overkleeft HS, Kaiser M. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem. 2009 10(16):2638-43.

5. Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft HS, Kalbacher H, Driessen C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia. 2009 23(6):1098-105

6. Kessler T, Reich M, Jahn G, Tolosa E, Beck A, Kalbacher H, Overkleeft H, Schempp S, Driessen C, Human cytomegalovirus infection interferes with major histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels. J Gen Virol. 2008 Oct; 89:2427-36. 

7. Stoeckle C, Sommandas V, Adamopoulou E, Belisle K, Schiekofer S, Melms A, Weber E, Driessen C, Boehm BO, Tolosa E, Burster T .Cathepsin G is differentially expressed in primary human antigen-presenting cells. Cell Immunol. 2009;255(1-2):41-5.

8. Kraus, M., Malenke, E., Gogel, J., Müller, H., Rückrich, T., Overkleeft, H., Ovaa, H., Koscielniak E., Hartmann, J., Driessen, C. Ritonavir induces ER-stress and sensitizes sarcoma cells towards bortezomib-induced apoptosis. Molecular Cancer Therapeutics 2008 Jul;7(7):1940-8    

9. Fissolo, N., Kraus, M., Reich, M., Ayturan, M., Overkleeft, H., Driessen, C., Weissert, R. Experimental Dual inhibition of lysosomal and proteasomal proteolysis ameliorates a model of multiple sclerosis
Eur J Immunol, 2008, Sept.; 38(9)2401-11.

10. Busse, A., Kraus, M., Il-Kang, N., Rietz, A., Scheibenbogen, C., Driessen, C., Blau, I., Thiel, E., Keilholz, U. Sensitivity of tumor cells to proteasome inhibitors is associated with expression level and composition of proteasome subunits. Cancer, 2008 Feb 1; 112(3): 659-70    

11. Horger, M., Pereira, P., Claussen, C., Kanz, L., Vonthein, R., Denecke, B., Driessen, C. Incidence and significance of hyperattenuating bone marrow abnormalities in myeloma patients referred for staging using whole-body nonenhanced low-dose MDCT and correlation with hematologic parameters: initial results. British J. of Radiology, 2008 May; 81(965): 386-96

12. Kraus M., Malenke E, Gogel J, Müller H, Rückrich T, Overkleeft H, Ovaa H, Koscielniak E. Hartmann JT, Driessen C. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Molecular cancer therapeutics 2008, 7: 1940-8